Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

elephone replay will be available through November 6, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non- nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the trial design, occurrence, timing, and pace of future clinical trials, the timing for obtaining viral load data and expectations regarding such data, as well as the anticipated future clinical benefits of ANA598 and ANA773. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. For example, the results of preclinical studies and early clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... San Francisco, CA (PRWEB) August 20, 2014 ... Medicine Conference is being held on October 29-30 ... fresh perspectives from industry, academic and government researchers and ... remaining in the space. , In the twelve ... than one hundred therapies have been introduced with pharmacogenetic ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient Outcome ... myPROpad™ ePRO tablet with the addition of a touchscreen ... widely used and well-respected Patient Reported Outcome (PRO) instruments ... used during clinical trials and in other health care ... to demonstrate Health-Related Quality of Life outcomes (HRQoL) resulting ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets ... Supplies - Global Strategic Business Report" report to their offering. ... and Tissue Culture Supplies in US$ Thousands by the following Product ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Latin America . Annual ...
(Date:8/19/2014)... 2014 Robin Williams’ passing is a ... on an individual. Symptoms range from slowness of ... swallowing and severe depression. Parkinson’s disease progressively gets ... dopamine producing neurons of the brain. As these ... slowly and progressively gets worse, they look for options. ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2EQ-5D™ Assessment Now Available for iPad 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... German . , The concept of confinement ... most famous example is that of quarks which bind together ... Helmholtz-Zentrum Berlin together with an international team of scientists report ... of confinement phenomenon observed in a condensed matter system. ...
... , DURHAM, N.C., Nov. 27 Cromoz Inc., located ... drug delivery system in Hyderabad, India. The water-soluble carbon nanotubes, ... conjugation with cancer drugs, was developed in partnership with the ... as a drug delivery vehicle with the ability to target ...
... ... helping bring complete automation to packaging quality assurance one step closer for ... by Sepha for use with blister packs and it has ... and Zydus-Cadilla to address quality assurance and productivity improvements on the packaging ...
Cached Biology Technology:Spinons -- confined like quarks 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3
(Date:8/20/2014)... 20, 2014  The second annual Biometrics UnPlugged ... Tampa, Florida on September 15, ... Rahman, Director, Technology and Strategy at Samsung, and Philippe ... theme of this year,s event is Mobility at ... "Biometrics UnPlugged: Mobility at the Crossroads of ...
(Date:8/19/2014)... Ecological Research and Network-Level Science, , Imagine if we ... of ecosystems was responding to global changes in real ... it coupled multiple decades of information about ecological responses ... from dozens of different ecosystem types. , In ... Research (LTER) Network, which will soon celebrate its 35th ...
(Date:8/19/2014)... a biomarker strongly associated with basal-like breast cancer, ... many types of chemotherapy. The biomarker, a protein ... therapeutics designed to treat this often deadly cancer. ... The Cancer Genome Atlas, molecular biologists Curt M. ... and bioinformatics techniques to detect patterns of gene ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... WI, October 21, 2010 Researchers at the University of ... Florida Water Management District have published a report regarding the ... report can be found in the September-October 2010 Journal ... Agronomy, the Crop Science Society of America, and the Soil ...
... How do humans and their environment interact, and how ... adapt to a planet undergoing far-reaching climate and other ... the National Science Foundation (NSF) has awarded 14 grants ... study coupled natural and human systems. Research conducted ...
... NY, October 21, 2010Antigene therapy is a promising new ... light energy to a target gene shutting down its ... in Oligonucleotides , a peer-reviewed journal published by ... possibilities and challenges for the clinical application of this ...
Cached Biology News:Everglades show improvement in water quality 2NSF awards grants for research on coupled natural and human systems 2NSF awards grants for research on coupled natural and human systems 3NSF awards grants for research on coupled natural and human systems 4NSF awards grants for research on coupled natural and human systems 5NSF awards grants for research on coupled natural and human systems 6Promising new 'antigene' therapy 2
... personal-sized Thermal Cycler is the ideal instrument for ... range of PCR applications. Get Applied ... Save lab space without sacrificing results. ... Industry-Standard PCR Technology You Can Afford ...
... The genus Salmonella is a member of ... Gram-negative bacilli that are facultative and flagellated (motile). ... flagellar antigen (phase 1 & 2), the "O" ... and the "Vi" or capsular antigen (referred to ...
... pyruvate, 50 mg/L streptomycin sulfate, 100 mg/L ... and magnesium chloride. The use of a ... is generally attributed to early workers in ... a solution of inorganic salts designed to ...
... a dramatic breakthrough in accurate, small-volume bulk dispensing. ... the micro 1 has unique advantages not found ... 1 never needs re-calibration as do other 1mL ... an LCD Display , Graphical Row Selection , ...
Biology Products: